InvestorsHub Logo
Followers 155
Posts 2647
Boards Moderated 0
Alias Born 01/29/2004

Re: tradeherpete post# 106168

Thursday, 05/25/2017 10:01:06 AM

Thursday, May 25, 2017 10:01:06 AM

Post# of 462573
So, the tau tangle thing again (any different?).

Merck, perhaps in desperation, collaborates with a Japanese pharmaceutical pursuing a tau protein removal drug. Good luck with that one. How many other Big Pharmas have spent billions testing both beta-amyloid and tau tangle removal drugs? Not a one has been successful in any way.

If this one can work, fine. Chances are slim, however. I'm not buying any Merck shares.

Once again, the target is an end-stage outcome. Beta-amyloids and tau tangles result at the end of the neuron dysfunction processes that cause Alzheimer's. This is where Anavex is so superior. It's drug, Anavex 2-73 treats the initial, first-stage problem, the disruption of the mitochondria-endoplasmic reticula interface. In normal, homeostatic neurons, the mitochondria are attached to the endoplasmic reticula and easily transfer adenosine triphosphate (ATP) to the ER, which allows it to properly fold proteins into fully-functioning enzymes, some of which clear the waste proteins, beta-amyloids, and tau tangles.

Anavex 2-73 fixes things before wastes accumulate, right at the start of the disease process, not the end. No other drug in consideration can do this. Unique, safe, and effective. Anavex 2-73, the eventual Standard of Care for a multitude of geriatric diseases.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News